[Ulrich2]

Please stop spreading lies. The paper is only about "The effectiveness of the first dose of BNT162 ..."

50% efficacy after the first dose is exactly the number that BioNTech reported in its Phase3 trial. So nothing unusual here. That is why the 2nd booster shot is needed to get to 95%.

[beagle3]

See my other reply to the other copy of your comment.

Please prove that you actually read the Pfizer report and not just repeating headlines before calling me a lier.

I might have misread some data, but I see no indication that you are in a position to judge that.